iShares Biotechnology ETF
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.36% less ownership
Funds ownership: 70.93% [Q4 2024] → 68.57% (-2.36%) [Q1 2025]
5% less funds holding
Funds holding: 863 [Q4 2024] → 818 (-45) [Q1 2025]
13% less capital invested
Capital invested by funds: $4.59B [Q4 2024] → $3.97B (-$618M) [Q1 2025]
27% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 8 (-3) [Q1 2025]
36% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 75
45% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 353
54% less call options, than puts
Call options by funds: $293M | Put options by funds: $630M
Research analyst outlook
We haven’t received any recent analyst ratings for IBB.
Financial journalist opinion
Based on 6 articles about IBB published over the past 30 days
Neutral
CNBC Television
1 day ago
Fast Money: WTI, IBB, UBER, CAT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Neutral
Zacks Investment Research
6 days ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Positive
See It Market
1 week ago
Biotechnology Sector ETF (IBB) Nears Important Pivot Point
As of the latest data available, the top three holdings in the iShares Biotechnology ETF (NASDAQ: IBB) are: These three companies collectively represent approximately 25.68% of the Biotechnology Sector ETF's total assets. With GILD in top technical position, AMGN and VRTX are also looking interesting.
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Positive
Seeking Alpha
2 weeks ago
IBB: Now Is The Time To Be Contrarian
Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks, the innovative pipeline, and AI-driven process improvements suggests the market may be missing the big picture. Institutional investors are getting back in on the action, evident from the strong Q1 in terms of deal activity.
Positive
CNBC Television
2 weeks ago
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.
Negative
Market Watch
1 month ago
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
Neutral
CNBC Television
1 month ago
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Neutral
See It Market
1 month ago
Key Stock Market ETFs, Bitcoin Creating A Story
This past week I wrote a lot about the relationship between silver, gold, bonds, the dollar and S&P 500. I also spoke in the media about those relationships as they are key right now to ascertain whether we are remaining in stagflation, heading towards recession, or resolving the uncertainty thereby seeing our way to growth.
Neutral
Zacks Investment Research
1 month ago
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Charts implemented using Lightweight Charts™